The delay in reporting data from the phase II trial by Ultragenyx Pharmaceutical Inc. with UX007 (triheptanoin, or trihep) in glucose transporter type-1 deficiency syndrome (Glut1 DS) patients with seizures may have tipped some investors that mixed results lay ahead with the compound, but Raymond James analyst Christopher Raymond said that, "with the Glut1 DS filing strategy still dependent on the pivotal phase III movement-disorder study, we do not see [the latest] data meaningfully changing trihep's opportunity in Glut1 DS."